Kazia Therapeutics Achieves Full Compliance with Nasdaq Listing Standards Following Major Financing

Kazia Therapeutics Regains Nasdaq Listing Compliance

Kazia Therapeutics Limited, a clinical-stage oncology firm based in Sydney, has proudly announced that it has restored its compliance with all Nasdaq listing standards. This significant milestone comes on the heels of a successful $50 million private placement led by institutional investors focused on healthcare. The financing not only bolsters Kazia’s balance sheet but also enhances its capability to pursue its ambitious oncology programs.

On December 18, 2025, Kazia received a formal written communication from Nasdaq confirming that the company meets the requirements stipulated under Listing Rule 5550(b)(1). This includes the minimum stockholders' equity requirement of $2.5 million, a crucial threshold that serves as an alternative to the minimum market value of listed securities (MVLS) requirement. Following this affirmation, Nasdaq also stated that all scheduled hearings related to the company’s potential non-compliance have been canceled as they are now deemed moot.

The resurgence of Nasdaq compliance signals a strengthening of Kazia’s financial framework and reliability in the eyes of investors. As Dr. John Friend, the Chief Executive Officer of Kazia, remarked, "This outcome reflects the progress we have made strengthening the company's financial position. With full Nasdaq compliance restored and a substantially enhanced balance sheet following our recent financing, we are well-positioned to focus on advancing our clinical programs and building long-term shareholder value."

The $50 million in financing was crucial for Kazia as it allows the company to focus on the development of its clinical-stage oncology pipeline. Its lead drug, paxalisib, is of particular interest as it targets multiple forms of brain cancer, including glioblastoma, and is currently involved in clinical trials assessing its effectiveness in combination with existing therapies for advanced triple-negative breast cancer. With this new influx of capital, Kazia aims to accelerate the development of these programs that could potentially change the treatment landscape for cancer patients.

Moreover, the restored compliance with Nasdaq enhances Kazia’s capability to operate within capital markets, providing clarity and building investor confidence. This revitalization ensures that the company can execute its strategic objectives more effectively while working towards important regulatory approvals and continued advancement of its drug pipeline.

Kazia Therapeutics remains committed to making significant strides in oncology by innovating treatments that prioritize patient outcomes. As the company looks forward to the future, it balances its scientific and financial ambitions with a focus on regulatory processes and market conditions. Investors and stakeholders alike remain optimistic about Kazia’s potential to deliver transformative therapies in the oncology space.

For more information regarding Kazia and its clinical programs, or to follow its journey, please contact Alex Star, Managing Director at LifeSci Advisors LLC.